;PMID: 1921930
;source_file_2866.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..31] = [t:0..31]
;1)sentence:[e:37..76] = [t:37..76]
;2)section:[e:80..112] = [t:80..112]
;3)section:[e:116..194] = [t:116..194]
;4)sentence:[e:198..302] = [t:198..302]
;5)sentence:[e:303..418] = [t:303..418]
;6)sentence:[e:419..581] = [t:419..581]
;7)sentence:[e:583..617] = [t:583..617]
;8)sentence:[e:618..685] = [t:618..685]
;9)sentence:[e:686..811] = [t:686..811]
;10)sentence:[e:812..935] = [t:812..935]
;11)sentence:[e:936..1040] = [t:936..1040]
;12)sentence:[e:1041..1152] = [t:1041..1152]
;13)sentence:[e:1153..1331] = [t:1153..1331]
;14)section:[e:1335..1379] = [t:1335..1379]

;section 0 Span:0..31
;Minn Med.  1991 Aug;74(8):23-6.
(SEC
  (FRAG (NNP:[0..4] Minn) (NNP:[5..8] Med) (.:[8..9] .) (CD:[11..15] 1991)
        (CC:[16..23] Aug;74-LRB-) (CD:[23..24] 8) (NN:[24..25] -RRB-)
        (::[25..26] :) (CD:[26..28] 23) (HYPH:[28..29] -) (CD:[29..31] 6.)))

;sentence 1 Span:37..76
;Incidentally discovered adrenal masses.
(SENT
  (NP-HLN
    (ADJP (RB:[37..49] Incidentally) (VBN:[50..60] discovered))
    (JJ:[61..68] adrenal) (NNS:[69..75] masses) (.:[75..76] .)))

;section 2 Span:80..112
;Caplan RH, Kisken WA, Huiras CM.
(SEC
  (FRAG (NNP:[80..86] Caplan) (NNP:[87..89] RH) (,:[89..90] ,)
        (NNP:[91..97] Kisken) (NNP:[98..100] WA) (,:[100..101] ,)
        (NNP:[102..108] Huiras) (NNP:[109..111] CM) (.:[111..112] .)))

;section 3 Span:116..194
;Department of Internal Medicine, Gundersen Clinic, Ltd., La Crosse,
;Wisconsin.
(SEC
  (FRAG (NNP:[116..126] Department) (IN:[127..129] of) (NNP:[130..138] Internal)
        (NNP:[139..147] Medicine) (,:[147..148] ,) (NNP:[149..158] Gundersen)
        (NNP:[159..165] Clinic) (,:[165..166] ,) (NNP:[167..171] Ltd.)
        (,:[171..172] ,) (NNP:[173..175] La) (NNP:[176..182] Crosse)
        (,:[182..183] ,) (NNP:[184..193] Wisconsin) (.:[193..194] .)))

;sentence 4 Span:198..302
;This report describes a retrospective study of 23 patients with incidentally 
;discovered adrenal masses.
(SENT
  (S
    (NP-SBJ (DT:[198..202] This) (NN:[203..209] report))
    (VP (VBZ:[210..219] describes)
      (NP
        (NP (DT:[220..221] a) (JJ:[222..235] retrospective)
            (NN:[236..241] study))
        (PP (IN:[242..244] of)
          (NP
            (NP (CD:[245..247] 23) (NNS:[248..256] patients))
            (PP (IN:[257..261] with)
              (NP
                (ADJP (RB:[262..274] incidentally) (VBN:[276..286] discovered))
                (JJ:[287..294] adrenal) (NNS:[295..301] masses)))))))
    (.:[301..302] .)))

;sentence 5 Span:303..418
;Two patients with subclinical cortisol secretion  developed adrenal
;insufficiency after removal of benign adenomas.
;[402..408]:malignancy-clinical-stage:"benign"
;[409..417]:malignancy-type:"adenomas"
(SENT
  (S
    (NP-SBJ
      (NP (CD:[303..306] Two) (NNS:[307..315] patients))
      (PP (IN:[316..320] with)
        (NP (JJ:[321..332] subclinical) (NN:[333..341] cortisol)
            (NN:[342..351] secretion))))
    (VP (VBD:[353..362] developed)
      (NP (JJ:[363..370] adrenal) (NN:[371..384] insufficiency))
      (PP-TMP (IN:[385..390] after)
        (NP
          (NP (NN:[391..398] removal))
          (PP (IN:[399..401] of)
            (NP (JJ:[402..408] benign) (NNS:[409..417] adenomas))))))
    (.:[417..418] .)))

;sentence 6 Span:419..581
;Another  patient, who probably harbors an asymptomatic pheochromocytoma,
;developed a  hypertensive crisis when a mass was palpated during aortic
;vascular surgery.
;[474..490]:malignancy-type:"pheochromocytoma"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[419..426] Another) (NN:[428..435] patient))
      (,:[435..436] ,)
      (SBAR
        (WHNP-1 (WP:[437..440] who))
        (S
          (NP-SBJ-1 (-NONE-:[440..440] *T*))
          (ADVP-SBJ (RB:[441..449] probably))
          (VP (VBZ:[450..457] harbors)
            (NP (DT:[458..460] an) (JJ:[461..473] asymptomatic)
                (NN:[474..490] pheochromocytoma))))))
    (,:[490..491] ,)
    (VP (VBD:[492..501] developed)
      (NP (DT:[502..503] a) (JJ:[505..517] hypertensive) (NN:[518..524] crisis))
      (SBAR
        (WHADVP-2 (WRB:[525..529] when))
        (S
          (NP-SBJ-3 (DT:[530..531] a) (NN:[532..536] mass))
          (VP (VBD:[537..540] was)
            (VP (VBN:[541..549] palpated)
              (NP-3 (-NONE-:[549..549] *))
              (PP (IN:[550..556] during)
                (NP (JJ:[557..563] aortic) (JJ:[564..572] vascular)
                    (NN:[573..580] surgery)))
              (ADVP-TMP-2 (-NONE-:[580..580] *T*)))))))
    (.:[580..581] .)))

;sentence 7 Span:583..617
;Twelve patients underwent surgery.
(SENT
  (S
    (NP-SBJ (CD:[583..589] Twelve) (NNS:[590..598] patients))
    (VP (VBD:[599..608] underwent)
      (NP (NN:[609..616] surgery)))
    (.:[616..617] .)))

;sentence 8 Span:618..685
;Seven benign adenomas, an angiomyolipoma, and  a cyst were removed.
;[624..630]:malignancy-clinical-stage:"benign"
;[631..639]:malignancy-type:"adenomas"
;[644..658]:malignancy-type:"angiomyolipoma"
(SENT
  (S
    (NP-SBJ-1
      (NP (CD:[618..623] Seven) (JJ:[624..630] benign) (NNS:[631..639] adenomas))
      (,:[639..640] ,)
      (NP (DT:[641..643] an) (NN:[644..658] angiomyolipoma))
      (,:[658..659] ,) (CC:[660..663] and)
      (NP (DT:[665..666] a) (NN:[667..671] cyst)))
    (VP (VBD:[672..676] were)
      (VP (VBN:[677..684] removed)
        (NP-1 (-NONE-:[684..684] *))))
    (.:[684..685] .)))

;sentence 9 Span:686..811
;Three patients had malignant masses that include an  angiosarcoma, an adrenal
;adenocarcinoma, and a congenital neuroblastoma.
;[705..714]:malignancy-clinical-stage:"malignant"
;[739..751]:malignancy-type:"angiosarcoma"
;[756..778]:malignancy-type:"adrenal adenocarcinoma"
;[786..796]:malignancy-developmental-state:"congenital"
;[797..810]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ (CD:[686..691] Three) (NNS:[692..700] patients))
    (VP (VBD:[701..704] had)
      (NP
        (NP (JJ:[705..714] malignant) (NNS:[715..721] masses))
        (SBAR
          (WHNP-1 (WDT:[722..726] that))
          (S
            (NP-SBJ-1 (-NONE-:[726..726] *T*))
            (VP (VBP:[727..734] include)
              (NP
                (NP (DT:[735..737] an) (NN:[739..751] angiosarcoma))
                (,:[751..752] ,)
                (NP (DT:[753..755] an)
                   (JJ:[756..763] adrenal) (NN:[764..778] adenocarcinoma))
                (,:[778..779] ,) (CC:[780..783] and)
                (NP (DT:[784..785] a) (JJ:[786..796] congenital)
                    (NN:[797..810] neuroblastoma))))))))
    (.:[810..811] .)))

;sentence 10 Span:812..935
;We  conclude that hormones, especially cortisol, may be secreted in
;subclinical  amounts by incidentally discovered masses.
(SENT
  (S
    (NP-SBJ (PRP:[812..814] We))
    (VP (VBP:[816..824] conclude)
      (SBAR (IN:[825..829] that)
        (S
          (NP-SBJ-1
            (NP (NNS:[830..838] hormones))
            (,:[838..839] ,)
            (NP
              (ADVP (RB:[840..850] especially))
              (NN:[851..859] cortisol)))
          (,:[859..860] ,)
          (VP (MD:[861..864] may)
            (VP (VB:[865..867] be)
              (VP (VBN:[868..876] secreted)
                (NP-1 (-NONE-:[876..876] *))
                (PP (IN:[877..879] in)
                  (NP (JJ:[880..891] subclinical) (NNS:[893..900] amounts)))
                (PP (IN:[901..903] by)
                  (NP-LGS
                    (ADJP (RB:[904..916] incidentally)
                          (VBN:[917..927] discovered))
                    (NNS:[928..934] masses)))))))))
    (.:[934..935] .)))

;sentence 11 Span:936..1040
;We recommend a concise laboratory  evaluation that includes an overnight
;dexamethasone suppression test.
(SENT
  (S
    (NP-SBJ (PRP:[936..938] We))
    (VP (VBP:[939..948] recommend)
      (NP
        (NP (DT:[949..950] a) (JJ:[951..958] concise) (NN:[959..969] laboratory)
            (NN:[971..981] evaluation))
        (SBAR
          (WHNP-1 (WDT:[982..986] that))
          (S
            (NP-SBJ-1 (-NONE-:[986..986] *T*))
            (VP (VBZ:[987..995] includes)
              (NP (DT:[996..998] an) (JJ:[999..1008] overnight)
                (NML (NN:[1009..1022] dexamethasone)
                     (NN:[1023..1034] suppression))
                (NN:[1035..1039] test)))))))
    (.:[1039..1040] .)))

;sentence 12 Span:1041..1152
;Based on  our interpretation of the literature, we believe masses greater
;than 3 cm in  size should be removed.
(SENT
  (S
    (PP (VBN:[1041..1046] Based)
      (PP (IN:[1047..1049] on)
        (NP
          (NP (PRP$:[1051..1054] our) (NN:[1055..1069] interpretation))
          (PP (IN:[1070..1072] of)
            (NP (DT:[1073..1076] the) (NN:[1077..1087] literature))))))
    (,:[1087..1088] ,)
    (NP-SBJ (PRP:[1089..1091] we))
    (VP (VBP:[1092..1099] believe)
      (S
        (NP-SBJ-1
          (NP (NNS:[1100..1106] masses))
          (ADJP (JJR:[1107..1114] greater)
            (PP (IN:[1115..1119] than)
              (NP
                (NP (CD:[1120..1121] 3) (NN:[1122..1124] cm))
                (PP (IN:[1125..1127] in)
                  (NP (NN:[1129..1133] size)))))))
        (VP (MD:[1134..1140] should)
          (VP (VB:[1141..1143] be)
            (VP (VBN:[1144..1151] removed)
              (NP-1 (-NONE-:[1151..1151] *)))))))
    (.:[1151..1152] .)))

;sentence 13 Span:1153..1331
;Patients who do not undergo surgery should have computed  tomographic scans
;repeated for one year and should be reassessed periodically  for the
;development of hormone secretion.
(SENT
  (S
    (NP-SBJ-2
      (NP (NNS:[1153..1161] Patients))
      (SBAR
        (WHNP-1 (WP:[1162..1165] who))
        (S
          (NP-SBJ-1 (-NONE-:[1165..1165] *T*))
          (VP (VBP:[1166..1168] do) (RB:[1169..1172] not)
            (VP (VB:[1173..1180] undergo)
              (NP (NN:[1181..1188] surgery)))))))
    (VP
      (VP (MD:[1189..1195] should)
        (VP (VB:[1196..1200] have)
          (S
            (NP-SBJ (VBN:[1201..1209] computed) (JJ:[1211..1222] tomographic)
                    (NNS:[1223..1228] scans))
            (VP (VBN:[1229..1237] repeated)
              (PP-TMP (IN:[1238..1241] for)
                (NP (CD:[1242..1245] one) (NN:[1246..1250] year)))))))
      (CC:[1251..1254] and)
      (VP (MD:[1255..1261] should)
        (VP (VB:[1262..1264] be)
          (VP (VBN:[1265..1275] reassessed)
            (NP-2 (-NONE-:[1275..1275] *))
            (ADVP-TMP (RB:[1276..1288] periodically))
            (PP (IN:[1290..1293] for)
              (NP
                (NP (DT:[1294..1297] the) (NN:[1298..1309] development))
                (PP (IN:[1310..1312] of)
                  (NP (NN:[1313..1320] hormone) (NN:[1321..1330] secretion)))))))))
    (.:[1330..1331] .)))

;section 14 Span:1335..1379
;PMID: 1921930 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1335..1339] PMID) (::[1339..1340] :) (CD:[1341..1348] 1921930)
        (NN:[1349..1350] -LSB-) (NNP:[1350..1356] PubMed) (::[1357..1358] -)
        (NN:[1359..1366] indexed) (IN:[1367..1370] for)
        (NNP:[1371..1379] MEDLINE-RSB-)))
